Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

NCT05792462 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT05792462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05792462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 15, 2023
Completion date
March 1, 2027
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nmo spectrum disorder